Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs in Medical Xerostomia
NCT06392711Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Oct 2024
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of Provacel in xerostomia (3 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Proportion of participants experiencing Dose-Limiting Toxicity (DLT) of submandibular pain at 1 month, Proportion of participants experiencing Dose-Limiting Toxicity (DLT) as serious adverse events (AEs) at 1 month and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
Provacel
03
Conditions
xerostomia
Beyond the preview
Go deeper on NCT06392711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06392711.